Literature DB >> 17043309

Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity.

Qian Yang1, Ken Inoki, Tsuneo Ikenoue, Kun-Liang Guan.   

Abstract

Target of rapamycin (TOR) is an evolutionally conserved protein kinase in eukaryotes and a central cell growth controller. TOR exists in two distinct complexes, termed TORC1 and TORC2. Mammalian TORC2 has recently been shown to possess kinase activity toward the C-terminal hydrophobic site of Akt/PKB. Here, we report that Sin1 is an essential component of TORC2 but not of TORC1, and functions similarly to Rictor, the defining member of TORC2, in complex formation and kinase activity. Knockdown of Sin1decreases Akt phosphorylation in both Drosophila and mammalian cells and diminishes Akt function in vivo. It also disrupts the interaction between Rictor and mTOR. Furthermore, Sin1 is required for TORC2 kinase activity in vitro. Disruption of the Rictor gene in mice results in embryonic lethality and ablates Akt phosphorylation. These data demonstrate that Sin1 together with Rictor are key components of mTORC2 and play an essential role in Akt phosphorylation and signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17043309      PMCID: PMC1619946          DOI: 10.1101/gad.1461206

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  40 in total

Review 1.  Will mTOR inhibitors make it as cancer drugs?

Authors:  Charles L Sawyers
Journal:  Cancer Cell       Date:  2003-11       Impact factor: 31.743

Review 2.  Advances in protein kinase B signalling: AKTion on multiple fronts.

Authors:  Derek P Brazil; Zhong-Zhou Yang; Brian A Hemmings
Journal:  Trends Biochem Sci       Date:  2004-05       Impact factor: 13.807

Review 3.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

4.  TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity.

Authors:  Qian Yang; Ken Inoki; Eunjung Kim; Kun-Liang Guan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-20       Impact factor: 11.205

5.  Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

Authors:  D D Sarbassov; Siraj M Ali; Do-Hyung Kim; David A Guertin; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Curr Biol       Date:  2004-07-27       Impact factor: 10.834

6.  Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase.

Authors:  Jianhua Feng; Jongsun Park; Peter Cron; Daniel Hess; Brian A Hemmings
Journal:  J Biol Chem       Date:  2004-07-15       Impact factor: 5.157

Review 7.  PDK1, the master regulator of AGC kinase signal transduction.

Authors:  Alfonso Mora; David Komander; Daan M F van Aalten; Dario R Alessi
Journal:  Semin Cell Dev Biol       Date:  2004-04       Impact factor: 7.727

8.  Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity.

Authors:  Sung Hee Um; Francesca Frigerio; Mitsuhiro Watanabe; Frédéric Picard; Manel Joaquin; Melanie Sticker; Stefano Fumagalli; Peter R Allegrini; Sara C Kozma; Johan Auwerx; George Thomas
Journal:  Nature       Date:  2004-08-11       Impact factor: 49.962

9.  Alternative polyadenylation and splicing of mRNAs transcribed from the human Sin1 gene.

Authors:  Wayne Schroder; Nicole Cloonan; Gillian Bushell; Tom Sculley
Journal:  Gene       Date:  2004-09-15       Impact factor: 3.688

10.  The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins.

Authors:  Laura S Harrington; Greg M Findlay; Alex Gray; Tatiana Tolkacheva; Simon Wigfield; Heike Rebholz; Jill Barnett; Nick R Leslie; Susan Cheng; Peter R Shepherd; Ivan Gout; C Peter Downes; Richard F Lamb
Journal:  J Cell Biol       Date:  2004-07-12       Impact factor: 10.539

View more
  249 in total

1.  Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Authors:  Kazuhiro Tanaka; Ivan Babic; David Nathanson; David Akhavan; Deliang Guo; Beatrice Gini; Julie Dang; Shaojun Zhu; Huijun Yang; Jason De Jesus; Ali Nael Amzajerdi; Yinan Zhang; Christian C Dibble; Hancai Dan; Amanda Rinkenbaugh; William H Yong; Harry V Vinters; Joseph F Gera; Webster K Cavenee; Timothy F Cloughesy; Brendan D Manning; Albert S Baldwin; Paul S Mischel
Journal:  Cancer Discov       Date:  2011-09-13       Impact factor: 39.397

2.  TOR complex 2 (TORC2) in Dictyostelium suppresses phagocytic nutrient capture independently of TORC1-mediated nutrient sensing.

Authors:  Daniel Rosel; Taruna Khurana; Amit Majithia; Xiuli Huang; Ramanath Bhandari; Alan R Kimmel
Journal:  J Cell Sci       Date:  2012-01-20       Impact factor: 5.285

Review 3.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

4.  TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion.

Authors:  Samy Lamouille; Erin Connolly; James W Smyth; Rosemary J Akhurst; Rik Derynck
Journal:  J Cell Sci       Date:  2012-03-07       Impact factor: 5.285

5.  Plasma membrane recruitment and activation of the AGC kinase Ypk1 is mediated by target of rapamycin complex 2 (TORC2) and its effector proteins Slm1 and Slm2.

Authors:  Brad J Niles; Huzefa Mogri; Andrew Hill; Ariadne Vlahakis; Ted Powers
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

6.  Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (mTOR) complex 2.

Authors:  Minsheng Yuan; Elizabeth Pino; Lianfeng Wu; Michael Kacergis; Alexander A Soukas
Journal:  J Biol Chem       Date:  2012-07-07       Impact factor: 5.157

7.  Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2.

Authors:  Delphine Boulbes; Chien-Hung Chen; Tattym Shaikenov; Nitin K Agarwal; Timothy R Peterson; Terri A Addona; Hasmik Keshishian; Steven A Carr; Mark A Magnuson; David M Sabatini; Dos D Sarbassov
Journal:  Mol Cancer Res       Date:  2010-05-25       Impact factor: 5.852

8.  Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells.

Authors:  Yu Gao; Ronald B Gartenhaus; Rena G Lapidus; Arif Hussain; Yanting Zhang; Xinghuan Wang; Han C Dan
Journal:  Mol Cancer Res       Date:  2015-09-15       Impact factor: 5.852

9.  Curcumin disrupts the Mammalian target of rapamycin-raptor complex.

Authors:  Christopher S Beevers; Long Chen; Lei Liu; Yan Luo; Nicholas J G Webster; Shile Huang
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

10.  Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.

Authors:  Y-P Jin; N M Valenzuela; M E Ziegler; E Rozengurt; E F Reed
Journal:  Am J Transplant       Date:  2014-03-01       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.